Pelvic Inflammatory Disease (PID) Treatment Market Report 2026

Pelvic Inflammatory Disease (PID) Treatment Market Overview

• Pelvic Inflammatory Disease (PID) Treatment market size has reached to $4.74 billion in 2025 • Expected to grow to $6.13 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: Increasing Sexually Transmitted Infections Drives The Growth Of The Market • Market Trend: Lee Health Domain Introduces V-Ferin For Vaginal Health • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pelvic Inflammatory Disease (PID) Treatment Market?

Pelvic inflammatory disease (PID) treatment refers to the medical management of infections affecting the female reproductive organs, typically caused by sexually transmitted bacteria such as Chlamydia trachomatis and Neisseria gonorrhoeae. Treatment aims to eliminate the infection, alleviate symptoms, and prevent complications such as infertility, chronic pelvic pain, and ectopic pregnancy. The main types of pelvic inflammatory disease (PID treatment are antibiotic therapy, surgery, pain management, and hormonal therapy. Antibiotic therapy is the use of antibiotics to treat bacterial infections by killing or inhibiting the growth of bacteria. It can be administered orally, intravenously, or intramuscularly, with PID treatment available in hospitals, clinics, and home care settings.

What Is The Pelvic Inflammatory Disease (PID) Treatment Market Growth Forecast?

The pelvic inflammatory disease (pid) treatment market size is expected to see strong growth in the next few years. It will grow to $6.13 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising adoption of combination antibiotic therapy, increasing use of hormonal therapy for prevention, advancements in minimally invasive surgical procedures, expanding telehealth and remote monitoring solutions, growing awareness and education programs for early detection. Major trends in the forecast period include increasing use of ai for early diagnosis and risk stratification, growing adoption of genomics-based personalized treatment approaches, integration of cloud and big data for patient monitoring and management, use of iot-enabled devices for remote symptom tracking, implementation of smart manufacturing in antibiotic production.

Global Pelvic Inflammatory Disease (PID) Treatment Market Segmentation

1) By Treatment Type: Antibiotic Therapy, Surgery, Pain Management 2) By Route Of Administration: Oral, Intravenous, Intramuscular 3) By End User: Hospitals, Clinics, Homecare Subsegments: 1) By Antibiotic Therapy: Broad-spectrum Antibiotics, Combination Antibiotic Therapy, Oral Antibiotics, Intravenous Antibiotics 2) By Surgery: Laparoscopy, Hysterectomy, Tubal Surgery 3) By Pain Management: Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Opioid Analgesics, Acetaminophen, Localized Pain Management

What Are The Drivers Of The Pelvic Inflammatory Disease (PID) Treatment Market?

The increasing prevalence of sexually transmitted infections is expected to propel the growth of the pelvic inflammatory disease (PID) treatment market going forward. Sexually transmitted infections (STIs) are infections caused by bacteria, viruses, or parasites that are primarily spread through sexual contact, including vaginal, anal, or oral sex. The increasing prevalence of sexually transmitted infections (STIs) is due to factors such as risky sexual behaviors, unprotected sex, lack of awareness, delayed testing, and treatment. Pelvic inflammatory disease (PID) treatment is useful for managing sexually transmitted infections (STIs) as it involves the use of antibiotics to eliminate infection-causing bacteria, prevents complications such as chronic pelvic pain and infertility, and reduces the risk of recurrent infections. For instance, in October 2024, according to a report published by the UK Health Security Agency (UKHSA), a UK-based government agency, in 2023, England recorded 6,008 new human immunodeficiency virus (HIV) diagnoses, marking a 51% increase compared to the 3,975 diagnoses in 2022. Therefore, the increasing prevalence of sexually transmitted infections is driving the growth of the pelvic inflammatory disease (PID) treatment industry. The rising adoption of telemedicine is expected to propel the growth of the telehealth solutions market going forward. Telemedicine refers to the delivery of healthcare services remotely through digital platforms, including video consultations, mobile health apps, and remote patient monitoring. The increasing adoption of telemedicine is due to factors such as the need for convenient access to care, shortage of healthcare professionals in certain regions, advancements in digital infrastructure, and patient preference for virtual consultations. Telehealth solutions are useful for managing patient care as they enable remote diagnosis and monitoring, improve access to healthcare services, reduce travel and waiting times, and support timely interventions for chronic and acute conditions. For instance, in March 2023, according to the Office of the National Coordinator for Health Information Technology (ONC), a US based government agency, reported that more than 80% of physicians used telemedicine for less than 50% percent of their patients. Therefore, the rising adoption of telemedicine is driving the growth of the pelvic inflammatory disease (PID) treatment industry.

Key Players In The Global Pelvic Inflammatory Disease (PID) Treatment Market

Major companies operating in the pelvic inflammatory disease (pid) treatment market are Pfizer Inc., Bayer AG, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Mayne Pharma Group Limited, Saphnix Lifesciences, Aristo Pharmaceuticals Pvt. Ltd., Zydus Cadila Healthcare Ltd., Amagen India Life Sciences

Global Pelvic Inflammatory Disease (PID) Treatment Market Trends and Insights

Major companies operating in the pelvic inflammatory disease (PID) treatment market are focusing on innovative formulations, such as probiotic supplements, to enhance treatment efficacy, restore vaginal microbiota balance, and reduce the recurrence of infections in patients with pelvic inflammatory disease (PID). A probiotic supplement is a product containing beneficial live bacteria or yeasts that help maintain or restore a healthy balance of gut and vaginal microbiota. For instance, in November 2024, Lee Health Domain, an India-based pharmaceutical company, launched V-Ferin, a probiotic supplement designed to support vaginal health. Formulated with Lactobacillus acidophilus, lactoferrin peptide, and cranberry extract, V-Ferin aims to restore the natural microbiome and prevent common vaginal infections like bacterial vaginosis and yeast infections. With around 25-30% of women affected by these conditions, which can lead to pelvic inflammatory disease if untreated, V-Ferin offers a novel solution to improve health and prevent complications.

Regional Outlook

North America was the largest region in the pelvic inflammatory disease (PID) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pelvic Inflammatory Disease (PID) Treatment Market?

The pelvic inflammatory disease (PID) treatment market consists of revenues earned by entities by providing services such as medication therapy, pain management, and hospital and clinic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pelvic inflammatory disease (PID) treatment market includes sales of antibiotics, pain relievers, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pelvic Inflammatory Disease (PID) Treatment Market Report 2026?

The pelvic inflammatory disease (pid) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pelvic inflammatory disease (pid) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.